Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD)
2015-000392-28Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) and diffuse cutaneous systemic sclerosis (dcSSc) comparing Nintedanib with Placebo (2 arms). Primary endpoint: Annual rate of decline in FVC in mL. Started Aug 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on 2015-000392-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000392-28.